Electrocardiographic status, changes in blood pressure and serum enzymes in dogs after administration of Vigabatrin

Document Type : (original research)

Authors

1 General Veterinary Administration of Zanjan Province, Iran Veterinary Organization, Zanjan, Iran

2 Department of Animal Science, Agriculture Faculty, Payam Noor University, Tehran, Iran

Abstract

Epilepsy is a common neurological disorder. The effect of antiepileptic drugs on cerebral blood flow has long been considered. One of the drugs used in the treatment of epilepsy is Vigabatrin, which is mainly used in the management of partial seizures and spasms. This drug is well absorbed after oral administration and 60 to 80% of it is excreted unchanged in the urine. It can also increase the level of amino butyric acid in the central nervous system by altering heart functional Heart, heart rate and blood pressure. In this study 12 dogs were randomly used. After cardiac studies and parasitic infections 5cc of blood samples were taken for serum studies. Vigabatrin was then administration orally at a dose of 500 mg per kg body weight per day for up to 7 days. After which an ECG was taken from the right side of the dogs without anesthesia and stress. The results were analyzed by one-way analysis of variance (ANOVA). Level of significance of the results was (p≤0.05).The results showed that the heart rate decreased and the PR and RR intervals increased.

Keywords

Main Subjects

References

  1. McClelland, D., Evans, R.M., Barkworth, L., Martin, D.J. and Scott, R.H., 2004. BMC.
  2. Monté, C.P., Arends, J.B., Tan, I.Y., Aldenkamp, A.P., Limburg, M. and de Krom, M.C., 2007. Sudden unexpected death in epilepsy patients: Risk factors. A systematic review. Seizure. 16(1): 1-7.
  3. James, W., Wheless, R., Eugene, R., Stephen, D. and Collins, V., 2007. The Journal of the American Society for Experimental Neuro Therapeutics. 4: 163-172.
  4. Hosking, S.L., Roff Hilton, E.J., Embleton, S.J. Gupta, A.K., 2003. Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow. Br J Ophthalmol. 87: 96-100.
  5. Singewald, N., Fitscher, A. and Philippu, A., 1992. Effects of gamma-vinyl GABA (vigabatrin) on blood pressure and body weight of hypertensive and normotensive rats, naunyn-schmiedeberg's archpharmacol. 345: 181-186.
  6. Tilly, L.P., Smith, Jr., Francis, W.K., Oyama, M.A. and Sleeper, M.M., 2008. Mannual of Canine and Feline Cardiology. Fourth Ed. Saunders Elsevier. 49-59.
  7. Loscher, W., 1982. Cardiovascular effects of GABA, GABA-aminotransferase inhibitors and valproic acid following systemic administration in rats, cats and dogs: pharmacological approach to localize the site of action, Arch Int Pharmacodyn Ther. 257(1): 32-58.
  8. Richens, A., McEwan, J.R., Deybach, J.C. and Mumford, J.P., 1997. Evidence for both in vivo and in vitro interaction between vigabatrin and alanine transaminase, Br J Clin Pharmacol. 43(2): 163-168.
  9. Trevor, J., Katzung, G. and Susan, B., 2007. Katzung & Trevor's Pharmacology Examination and Board Review, First Ed. McGraw-Hill Professional. 359-472.
  10. Okumura, H., Omote, M. and Takeshita, S., 1996. In vitro effects of the novel anti-epileptic agent vigabatrin on alanine aminotransferase and aspartate aminotransferase activities in rat serum. Arzne imittel forschung. 46(5):
    459-462.
  11. Cheung, M.Y. and Viney, M., 2007. Anesth Analg. 105(4): 1127-1129.
  12. Kondo, T., Fromm, G.H. and Schmidt, B., 1991. Epilepsy Res. 8(3): 226-231.
  13. Guerrero-Figueroa, R., Escobar-Juyo, A., Caballero García, G. and Blanco-Castillo, I.P., 1999. Rev Neurol. 29(12): 1147-1153.
  14. Alden, K.J. and García, J., 2001. J Pharmacol Exp Ther. 297(2): 727-235.
  15. Boroujerdi, A., Kim, H.K., Lyu, Y.S., Kim, D.S., Figueroa, K.W., Chung, J.M. and Luo, Z.D., 2008. 139(2): 358-366.
  16. Libby, P., Bonow, R.O., Mann, D.L. and Zipes, D.P., 2008. Braunwald's Heart Disease, Eighth Ed. Philadelphia, Saunders Elsevier. 149-974.
Journal of Animal Environment
Volume 14, Issue 2
July 2022
Pages 103-106

Files

Share

How to cite

Statistics